CrushSCI.com
71平均天数
66中位天数
25最短天数
160最长天数
1012025发文量

Paper Review Records

全部论文审稿周期

16 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

25 天

Comparative efficacy of CLDN18.2-directed regimens in advanced gastric/gastroesophageal junction adenocarcinoma: a meta-analysis of single-arm trials

作者
Yue Yuan; Hongkai Yan; Qinhang Wu展开收起
作者单位
1. School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China展开收起
PDF源文件 DOI 网页
27 天

Effector-to-target ratio as a translational bottleneck for CD33 T-cell engagers in acute myeloid leukemia: a quantitative reanalysis of AMG 330

作者
Hamid Bellout展开收起
作者单位
1. Northern Illinois University, DeKalb, USA展开收起
PDF源文件 DOI 网页
89 天

Preclinical evaluation and mechanistic analysis of antitumor effects of the novel anti-CD147 antibody DS-1471a in liver cancer models

作者
Hiroshi Yuita; Sadanori Watanabe; Jun Tsukada; Yoshikazu Johmura; Sae Aratani; Hirokazu Ishikawa; Ryuichi Nakamura; Miki Yokoyama; Mari Hashimoto; Hideo Yukinaga; Huynh The Hung; Makoto Nakanishi; Keisuke Fukuchi展开收起
作者单位
1. Translational Science Department II, Daiichi Sankyo Co., Ltd., Tokyo, Japan; 2. Discovery Research Laboratories I, Daiichi Sankyo Co., Ltd., Tokyo, Japan; 3. Division of Cancer and Senescence Biology, Cancer Research Institute, Institute for Frontier Science Initiative, Kanazawa University, Kanazawa, Japan; 4. Division of Cancer Cell Biology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; 5. Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan; 6. Translational Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan; 7. Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan; 8. Daiichi Sankyo Inc., Basking Ridge, USA; 9. Division of Cellular and Molecular Research, National Cancer Centre, Singapore, Singapore展开收起
PDF源文件 DOI 网页
76 天

A phase 1 study of PF-07260437, a B7-H4 × CD3 bispecific T-cell engager, in patients with advanced or metastatic breast, ovarian, and endometrial cancer

作者
Fengting Yan; Marcia Cruz-Correa; Jennifer Specht; Edward Wenge Wang; Jinyu Lu; Hatem Soliman; Amy Jackson-Fisher; Szu-Yu Tang; Sibo Jiang; Christophe Le Corre; Meng Li; David Sommerhalder展开收起
作者单位
1. Swedish Cancer Institute, Seattle, USA; 2. Pan American Center for Oncology Trials, San Juan, USA; 3. Fred Hutchinson Cancer Center, Seattle, USA; 4. City of Hope Comprehensive Cancer Center, Duarte, USA; 5. Montefiore Einstein Comprehensive Cancer Center, Bronx, USA; 6. Moffitt Cancer Center, Tampa, USA; 7. Pfizer, San Diego, USA; 8. Pfizer, South San Francisco, USA; 9. NEXT Oncology, San Antonio, USA展开收起
PDF源文件 DOI 网页
136 天

Preclinical and clinical evaluation of futibatinib in combination with binimetinib in patients with advanced cancer

作者
Jordi Rodon; Bert O’Neil; Christopher Lim; Natraj R. Ammakkanavar; Carlos Torrado; Kazuaki Matsuoka; Hiroshi Hirai; Akihiro Miura; Bailey Anderson; Leah Jin; Nanae Hangai; Amanda Long; Volker Wacheck; Lee Rosen展开收起
作者单位
1. MD Anderson Cancer Center, Houston, USA; 2. Community Health Network, Indianapolis, USA; 3. Division of Hematology-Oncology, UCLA, Los Angeles, USA; 4. Taiho Pharmaceutical Co. Ltd, Tokyo, Japan; 5. Taiho Oncology, Inc., Princeton, USA展开收起
PDF源文件 DOI 网页
88 天

A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer

作者
Khobe Chandran; Christina Guo; Simon Pacey; Guillermo Villacampa; Ruth Matthews; Toby Prout; Joan Fernandes; Alison Turner; Mona Parmar; Ruth Riisnaes; Ana Ferreira; Suzanne Carreira; Claudia Bertan; Mateus Crespo; Ines Figueiredo; Wei Yuan; Denisa Bogdan; Florence Raynaud; Ruth Ruddle; Bianca Calì; Martino Maddalena; Arianna Calcinotto; Christina Yap; Adam Sharp; Andrea Alimonti; Johann De Bono; Alec Paschalis展开收起
作者单位
1. Institute of Cancer Research, London, UK; 2. The Royal Marsden NHS Foundation Trust, London, UK; 3. Department of Oncology, School of Clinical Medicine, University of Cambridge, Cambridge, UK; 4. Cambridge University Hospitals NHS Foundation Trust, Addenbrookes Hospital, Cambridge, UK; 5. Institute of Oncology Research (IOR), Bellinzona, Switzerland; 6. Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland; 7. Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; 8. Department of Health Sciences and Technology, Eidgenössische Technische Hochschule Zürich (ETH), Zurich, Switzerland; 9. Department of Medicine, University of Padova, Padua, Italy展开收起
PDF源文件 DOI 网页

FAQ

INVESTIGATIONAL NEW DRUGS审稿要多久?

截至2026-11-19,CrushSCI 收录了 INVESTIGATIONAL NEW DRUGS 的 16 篇完整审稿记录。最快一篇从收稿到录用用了 25 天(Comparative efficacy of CLDN18.2-directed regimens in advanced gastric/gastroesophageal junction adenocarcinoma: a meta-analysis of single-arm trials,2026-08-12 收稿,2026-09-06 录用),最慢一篇用了 160 天;平均 71 天,中位数 66 天。

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

我们会在半小时内回复。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿59.6 天

中位数65 天

Contact CrushSCI

联系 CrushSCI

留下手机号或微信号,我们将与你确认学术润色、结构优化或一对一辅导咨询需求。

我们会在半小时内回复。

当前选择:学术咨询服务

预留联系方式

也可以直接发送邮件至 leader@crushsci.com

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。